Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Exelixis, Inc.

< Previous 1 2 3 4 Next >
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Advances Board Refreshment Plan
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Reiterates Commitment to Shareholder Value Creation
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces $550 Million Share Repurchase Program
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Update on Patent Litigation with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.